HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ivax ethnic H&BA, derm business likely spin-off from merger with Bergen Brunswig.

This article was originally published in The Rose Sheet

Executive Summary

IVAX POSSIBLE SPIN-OFF OF ETHNIC H&BA, DERM PRODUCTS appears likely in light of Bergen Brunswig's professed focus on Ivax' generic prescription drug business and proprietary pharmaceuticals pipeline following the proposed merger of the two companies announced Nov. 11. Miami, Fla.-based Ivax in the past has identified its ethnic H&BA business as a potential spin-off candidate. Sales for the ethnic and dermatologicals businesses in 1995 were roughly $63 mil.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel